PO.IM01.11 · 免疫学

免疫检查点治疗在三阴性乳腺癌小鼠模型中诱导三级淋巴结构

Immune checkpoint therapy induces tertiary lymphoid structures in a murine model of triple-negative breast cancer

海报缩略图:免疫检查点治疗在三阴性乳腺癌小鼠模型中诱导三级淋巴结构
编号 2817 展板 22 时间 4/20 02:00–05:00 区域 Section 7 主讲 Zachary Schrank, BA
分会场 Immune Checkpoints
查看 PDF 下载 PDF 🔒 查看 / 下载完整 PDF 需登录并开通下载套餐 · 查看套餐 / 开通 AACR 官方页面

作者与单位 Authors & Affiliations

Zachary D. Schrank, Benjamin G. Vincent, Jonathan S. Serody

University of North Carolina School of Medicine, Chapel Hill, NC

摘要 Abstract

中文摘要
背景:尽管免疫检查点治疗(ICT)已被批准用于治疗三阴性乳腺癌(TNBC),但反应率低且不持久。因此迫切需要更好的治疗性生物标志物以及对TNBC抗肿瘤免疫反应的更深入理解,以定制更优的免疫治疗。三级淋巴结构(TLS)是由B细胞和T细胞组成的肿瘤内淋巴组织,与生存改善和ICT反应相关。尽管存在这些关联,ICT对这些结构有何影响以及它们是否介导ICT疗效尚不清楚。我们试图探讨ICT是否可促进TNBC中TLS的形成。 方法与结果:在本研究中,我们在原位鼠源TNBC模型中显示免疫检查点治疗(抗PD-1和抗CTLA-4)后TLS的诱导。该模型T11-APOBEC在基因层面模拟临床TNBC,且其对免疫检查点治疗的反应依赖于B细胞和CD4+ T细胞。使用免疫荧光,我们显示ICT后T11-APOBEC肿瘤外周的TLS形成显著上调,而接受赋形剂对照治疗的肿瘤几乎不形成TLS(p = 0.0286)。这些TLS由B细胞与CD4+和CD8+ T细胞聚集组成,并且还与促炎性巨噬细胞和单核细胞相关。使用空间转录组学和K近邻分析,我们以无偏方式显示这些TLS被识别为空间和转录上独特的生态位。该模型中的TLS显著富集四种广泛使用的人类癌症相关TLS转录特征,并且还显著上调与B细胞活化、体液免疫和生发中心活性相关的通路。我们进一步显示,通过空间转录组学,源自这些ICT诱导TLS的特征在一组人类TNBC样本队列中呈局灶性富集,提示TNBC患者中形成了类似结构。 结论:这些数据提示ICT促进TNBC中TLS的形成,这可能介导增强的抗肿瘤适应性免疫反应。该模型还提供了一个平台,用于在ICT背景下进一步研究这些结构的形成和功能机制,这将为这种侵袭性疾病的预测性生物标志物和改进的免疫治疗方法提供依据。
查看英文原文 English abstract
Background: Though immune checkpoint therapy (ICT) is approved for the treatment of triple-negative breast cancer (TNBC), response rates are low and non-durable. There is thus an urgent need for improved therapeutic biomarkers and deeper understanding of TNBC antitumor immune responses to tailor improved immunotherapies. Tertiary lymphoid structures (TLS) are intra-tumoral lymphoid tissues composed of B cells and T cells that are associated with improved survival and response to ICT. Despite these associations, it is unclear what impact ICT has on these structures and whether they mediate ICT efficacy. We sought to examine if ICT may promote formation of TLS in TNBC. Methods and Results: In this study, we show induction of TLS following immune checkpoint therapy (anti-PD-1 and anti-CTLA-4) in an orthotopic murine TNBC model. This model, T11-APOBEC, genocopies clinical TNBC and is dependent upon B cells and CD4 + T cells for response to immune checkpoint therapy. Using immunofluorescence, we show that TLS formation is significantly upregulated in the periphery of T11-APOBEC tumors following ICT, whereas tumors treated with vehicle control show little to no TLS formation (p = 0.0286). These TLS are composed of B cells coalescing with CD4 + and CD8 + T cells and are also associated with pro-inflammatory macrophages and monocytes. Using spatial transcriptomics and K-nearest neighbor analysis, we show that these TLS are identified as a spatially and transcriptionally distinct niche in an unbiased manner. TLS in this model are significantly enriched for four widely used transcriptional signatures of human cancer-associated TLS, and they also significantly upregulate pathways associated with B cell activation, humoral immunity, and germinal center activity. We then further show that a signature derived from these ICT-induced TLS are focally enriched in a cohort of human TNBC samples by spatial transcriptomics, suggesting the formation of similar structures in TNBC patients. Conclusions: These data suggest that ICT promotes the formation of TLS in TNBC, which may mediate enhanced anti-tumor adaptive immune responses. This model also provides a platform to further investigate mechanisms of formation and function of these structures in the context of ICT, which will inform predictive biomarkers and improved immunotherapy approaches for this aggressive disease.
利益披露 Disclosure
Z. D. Schrank, None. B. G. Vincent, Consultant Independent Contractor. Pathfinder Oncology Stock, Other, Co-founder. J. S. Serody, None.

← 返回 AACR 2026 检索